FDA to Consider Easing Restrictions on Unproven Peptides

The move follows calls from RFK Jr. and MAHA supporters to loosen regulations on the unapproved therapies.

Apr. 16, 2026 at 12:39am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the complex molecular structure of a peptide, conceptually illustrating the FDA's review of these unregulated health supplements.As the FDA considers easing restrictions on unproven peptide therapies, concerns grow over the potential health risks of these unapproved substances.Washington Today

The Food and Drug Administration will hold a meeting this summer to consider easing restrictions on more than a half dozen peptide injections, a group of unapproved therapies that have become popular among wellness influencers, fitness gurus and celebrities. The meeting announcement follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on peptides, which are often pitched as a quick way to build muscle, heal injuries or appear younger.

Why it matters

The FDA's potential move to ease restrictions on these unproven peptides raises concerns about public health and safety, as most of these substances have not undergone rigorous clinical testing for efficacy and potential side effects. This decision could open the door for a less regulated market of these products, which some experts warn poses a "profound threat" to the FDA's established drug approval process.

The details

The FDA said it will ask a panel of outside advisers to review seven peptides at a meeting in July, specifically whether they should be added to a list of substances that can be safely produced by pharmacies. In the meantime, the agency said it would soon remove the chemicals from a restrictive list reserved for unapproved, high-risk drugs. The peptides under discussion include some of the most popular among influencers, such as BPC-157, which is marketed to heal injuries and reduce inflammation.

  • The FDA meeting is scheduled for July 2026.
  • The agency plans to remove the peptides from its list of restricted substances in the near future.

The players

Robert F. Kennedy Jr.

The U.S. Health Secretary who has repeatedly called for loosening regulations on peptides, which he claims to have personally used with good effect.

Gary Brecka

A self-described "longevity expert" who sells various peptide formulas through his website and is a major supporter of the Make America Healthy Again (MAHA) movement.

Dr. Peter Lurie

A former FDA official who now leads the Center for Science in the Public Interest, and who believes allowing peptides on the market without clinical testing poses a "profound threat" to the FDA's drug approval process.

Dr. Eric Topol

A researcher at Scripps Research Translational Institute who has studied the issue of peptides and believes "these peptides have no data to support their safety and efficacy."

Scott Brunner

A representative of the Alliance for Pharmacy Compounding, who says the upcoming FDA meeting will be the start of a "protracted process" even if the panel votes to make the peptides available.

Got photos? Submit your photos here. ›

What they’re saying

“I'm a big fan of peptides. I've used them myself and with really good effect on a couple of injuries.”

— Robert F. Kennedy Jr., U.S. Health Secretary

“The Wild West is about to become wilder.”

— Dr. Peter Lurie, Former FDA Official, Center for Science in the Public Interest

“I don't see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market.”

— Dr. Peter Lurie, Former FDA Official, Center for Science in the Public Interest

“These peptides have no data to support their safety and efficacy.”

— Dr. Eric Topol, Scripps Research Translational Institute

“With the gray market you have no idea if you're getting a good product. And a lot of this stuff that we've looked at is just very, very substandard.”

— Robert F. Kennedy Jr., U.S. Health Secretary

What’s next

The FDA panel will meet in July 2026 to review the seven peptides and determine whether they should be added to the list of substances that can be safely produced by compounding pharmacies. If the panel votes to allow the peptides, the FDA will then have to draft and publish new rules on their production and distribution.

The takeaway

The FDA's potential move to ease restrictions on unproven peptides despite safety concerns highlights the growing influence of alternative health movements and the challenges in balancing innovation with public health protections. This decision could open the door to a less regulated market of these products, which some experts warn poses a serious threat to the FDA's established drug approval process.